With regard to the suitable effector T-cell phenotype for anti-CNS tumor immunotherapy, our previous studies have demonstrated that expression of IFN-γ by T-cells[20] and the resulting expression of IFN-inducible protein (IP)-10, also known as CXCL10, in the CNS tumor environment[21,22], are critically important. Here, IFNG is linked to central nervous system neoplasm.